Dievini Hopp Shows Mettle for EU Biotech Investing
By Cormac Sheridan
Staff Writer
Staff Writer
The €80 million (US$104.9 million) investment by dievini Hopp BioTech Holding GmbH & Co. KG in Tuebingen, Germany-based CureVac GmbH is not only its single biggest bet to date, but also a clear point of differentiation between itself and most other private investors in European biotechnology.
